Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Astrazeneca Plc ADR (AZN)

Astrazeneca Plc ADR (AZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 240,103,664
  • Shares Outstanding, K 3,100,512
  • Annual Sales, $ 45,811 M
  • Annual Income, $ 5,955 M
  • EBIT $ 9,049 M
  • EBITDA $ 14,436 M
  • 60-Month Beta 0.46
  • Price/Sales 5.30
  • Price/Cash Flow 14.50
  • Price/Book 6.13

Options Overview Details

View History
  • Implied Volatility 31.30% ( +0.86%)
  • Historical Volatility 13.97%
  • IV Percentile 99%
  • IV Rank 99.66%
  • IV High 31.35% on 10/17/24
  • IV Low 15.77% on 05/28/24
  • Put/Call Vol Ratio 1.32
  • Today's Volume 1,800
  • Volume Avg (30-Day) 7,113
  • Put/Call OI Ratio 0.90
  • Today's Open Interest 123,132
  • Open Int (30-Day) 120,011

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate 1.03
  • Number of Estimates 5
  • High Estimate 1.09
  • Low Estimate 0.98
  • Prior Year 0.87
  • Growth Rate Est. (year over year) +18.39%

Price Performance

See More
Period Period Low Period High Performance
1-Month
76.41 +1.19%
on 10/09/24
79.76 -3.06%
on 10/02/24
-1.06 (-1.35%)
since 09/20/24
3-Month
76.41 +1.19%
on 10/09/24
87.68 -11.81%
on 08/30/24
-1.84 (-2.32%)
since 07/22/24
52-Week
60.47 +27.87%
on 02/12/24
87.68 -11.81%
on 08/30/24
+13.49 (+21.13%)
since 10/20/23

Most Recent Stories

More News
GSK's Studies on Depemokimab for Nasal Polyps Meet Primary Goals (Revised)

GSK plc GSK announced positive data from the phase III ANCHOR-1 and ANCHOR-2 studies, which evaluated its pipeline candidate, depemokimab, for treating adults with chronic rhinosinusitis with nasal polyps...

AZN : 77.32 (-0.15%)
REGN : 962.34 (-0.64%)
GSK : 38.00 (-0.42%)
SNY : 53.26 (-0.75%)
GSK's Studies on Depemokimab for Nasal Polyps Meet Primary Goals

GSK plc GSK announced positive data from the phase III ANCHOR-1 and ANCHOR-2 studies, which evaluated its pipeline candidate, depemokimab, for treating adults with chronic rhinosinusitis with nasal polyps...

AZN : 77.32 (-0.15%)
REGN : 962.34 (-0.64%)
GSK : 38.00 (-0.42%)
SNY : 53.26 (-0.75%)
J&J Beats on Q3 Earnings, Raises Sales View but Cuts EPS Guidance

Johnson & Johnson’s JNJ third-quarter 2024 earnings came in at $2.42 per share, which beat the Zacks Consensus Estimate of $2.22. Earnings declined 9% from the year-ago period.Adjusted earnings exclude...

AZN : 77.32 (-0.15%)
JNJ : 163.45 (+0.38%)
LLY : 909.15 (+0.33%)
KVUE : 22.93 (+0.04%)
1 'Strong Buy' Penny Stock to Invest in AI Drug Development

Investors seeking AI-led drug development opportunities can consider this top-rated biotech stock under $5.

AZN : 77.32 (-0.15%)
ABSI : 4.14 (+2.48%)
Want to Invest in the Weight Loss Boom? Consider Buying These 2 Stocks

Investing in the most popular players in the space isn't the only valid approach.

AZN : 77.32 (-0.15%)
LLY : 909.15 (+0.33%)
AMGN : 319.66 (+0.92%)
Zacks Industry Outlook Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer

For Immediate ReleaseChicago, IL – October 8, 2024 – Today, Zacks Equity Research Eli Lilly LLY, AstraZeneca AZN, Pfizer PFE, Sanofi SNY and Bayer BAYRY.Industry: Big PharmaLink: https://www.zacks.com/commentary/2346520/5-large-drug-stocks-to-watch-from-a-thriving-industryThe...

BAYRY : 7.0200 (-0.71%)
AZN : 77.32 (-0.15%)
LLY : 909.15 (+0.33%)
PFE : 28.84 (-0.31%)
SNY : 53.26 (-0.75%)
5 Large Drug Stocks to Watch From a Thriving Industry

The drug and biotech industry has done well this year, driven by increased mergers and acquisitions (M&A), the launch of promising new medicines and pipeline successes. Obesity drugs of Novo Nordisk and...

BAYRY : 7.0200 (-0.71%)
AZN : 77.32 (-0.15%)
LLY : 909.15 (+0.33%)
PFE : 28.84 (-0.31%)
SNY : 53.26 (-0.75%)
Pharma Stock Roundup: FDA Approves SNY's Dupixent for COPD & More

This week, the FDA granted approval to Sanofi SNY and Regeneron’s REGN blockbuster drug, Dupixent, for its sixth indication. The FDA also granted priority review designation to AstraZeneca’s AZN label...

AZN : 77.32 (-0.15%)
LLY : 909.15 (+0.33%)
ABBV : 188.76 (+1.19%)
REGN : 962.34 (-0.64%)
SNY : 53.26 (-0.75%)
AbbVie Cuts 2024 Earnings Guidance to Include Acquisition Costs

AbbVie ABBV announced in a regulatory filing that it is lowering its previously issued guidance for 2024 adjusted earnings per share by 4 cents per share to account for acquired in-process research and...

BAYRY : 7.0200 (-0.71%)
AZN : 77.32 (-0.15%)
LLY : 909.15 (+0.33%)
ABBV : 188.76 (+1.19%)
Eli Lilly to Invest $4.5B for New Manufacturing & Research Plant

Eli Lilly and Company LLY announced a significant $4.5 billion investment for the establishment of the Lilly Medicine Foundry in Indiana to advance drug production and innovation. This facility will enable...

AZN : 77.32 (-0.15%)
NVO : 116.47 (-0.73%)
LLY : 909.15 (+0.33%)
SNY : 53.26 (-0.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition...

See More

Key Turning Points

3rd Resistance Point 78.32
2nd Resistance Point 77.87
1st Resistance Point 77.59
Last Price 77.32
1st Support Level 76.86
2nd Support Level 76.41
3rd Support Level 76.13

See More

52-Week High 87.68
Last Price 77.32
Fibonacci 61.8% 77.28
Fibonacci 50% 74.07
Fibonacci 38.2% 70.86
52-Week Low 60.47

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar